CEO: Wolfgang Renner

Advent Contact: Iyona Rajkomar

Novel oligonucleotide chemistry platform for inherited genetic diseases

Alpha Anomeric is using a novel, proprietary oligonucleotide chemistry platform for the design of a new class of exon skipping agents. These will be evaluated for the treatment of certain inherited genetic diseases, initially in patients with Duchenne’s Muscular Dystrophy.

Advent co-founded Alpha Anomeric in 2018 and was the sole investor in the Series A.

Back